[go: up one dir, main page]

BRPI1016026A2 - composição, métodos para regular uma atividade nervosa autônoma, para promover a atividade nervosa parassimpática, para suprimir um aumento em uma atividade nervosa simpática em um animal não humano, para promover a motilidade gastrointestinal, para prevenir a amnésia, e, para reduzir a ansiedade, e, agente. - Google Patents

composição, métodos para regular uma atividade nervosa autônoma, para promover a atividade nervosa parassimpática, para suprimir um aumento em uma atividade nervosa simpática em um animal não humano, para promover a motilidade gastrointestinal, para prevenir a amnésia, e, para reduzir a ansiedade, e, agente.

Info

Publication number
BRPI1016026A2
BRPI1016026A2 BRPI1016026A BRPI1016026A BRPI1016026A2 BR PI1016026 A2 BRPI1016026 A2 BR PI1016026A2 BR PI1016026 A BRPI1016026 A BR PI1016026A BR PI1016026 A BRPI1016026 A BR PI1016026A BR PI1016026 A2 BRPI1016026 A2 BR PI1016026A2
Authority
BR
Brazil
Prior art keywords
nerve activity
promoting
suppressing
composition
methods
Prior art date
Application number
BRPI1016026A
Other languages
English (en)
Portuguese (pt)
Inventor
Hidehiko Baba
Kazuhito Ohsawa
Kohji Ohki
Naoto Uchida
Yasunori Nakamura
Original Assignee
Calpis Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calpis Co Ltd filed Critical Calpis Co Ltd
Publication of BRPI1016026A2 publication Critical patent/BRPI1016026A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI1016026A 2009-03-27 2010-03-26 composição, métodos para regular uma atividade nervosa autônoma, para promover a atividade nervosa parassimpática, para suprimir um aumento em uma atividade nervosa simpática em um animal não humano, para promover a motilidade gastrointestinal, para prevenir a amnésia, e, para reduzir a ansiedade, e, agente. BRPI1016026A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009078015 2009-03-27
PCT/JP2010/055413 WO2010110439A1 (ja) 2009-03-27 2010-03-26 自律神経活動調節用組成物および自律神経を調節する方法

Publications (1)

Publication Number Publication Date
BRPI1016026A2 true BRPI1016026A2 (pt) 2016-05-10

Family

ID=42781129

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1016026A BRPI1016026A2 (pt) 2009-03-27 2010-03-26 composição, métodos para regular uma atividade nervosa autônoma, para promover a atividade nervosa parassimpática, para suprimir um aumento em uma atividade nervosa simpática em um animal não humano, para promover a motilidade gastrointestinal, para prevenir a amnésia, e, para reduzir a ansiedade, e, agente.

Country Status (11)

Country Link
US (1) US20120015882A1 (ja)
EP (1) EP2412379A4 (ja)
JP (1) JP5677937B2 (ja)
KR (1) KR20110136879A (ja)
CN (1) CN102448480A (ja)
BR (1) BRPI1016026A2 (ja)
CA (1) CA2756107A1 (ja)
MX (1) MX2011010077A (ja)
SG (1) SG174456A1 (ja)
TW (1) TW201039839A (ja)
WO (1) WO2010110439A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6098929B2 (ja) * 2013-02-22 2017-03-22 国立大学法人京都大学 抗うつ剤又は抗不安剤
CN107517585A (zh) * 2015-05-13 2017-12-26 朝日可尔必思健康株式会社 抑制运动时的心率上升的方法和抑制心率上升的组合物
CN113896761A (zh) * 2021-09-15 2022-01-07 湖北泓肽生物科技有限公司 一种l-酪氨酰-l-脯氨酸的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3047596A1 (de) * 1980-12-17 1982-07-22 Victor Dipl.- Chem. 8000 München Brantl Pharmakologisch aktive dipeptide
US4931430A (en) * 1987-12-14 1990-06-05 E. R. Squibb & Sons, Inc. Method for preventing or treating anxiety employing an ACE inhibitor
IL88502A (en) * 1987-12-14 1993-04-04 Squibb & Sons Inc Pharmaceutical compositions containing an angiotensin converting enzyme inhibitor
JP3193763B2 (ja) 1992-03-03 2001-07-30 日清製粉株式会社 ペプチド
SE9600120D0 (sv) * 1996-01-15 1996-01-15 Astra Ab Novel medical use
US5854029A (en) * 1996-08-02 1998-12-29 Calpis Co., Ltd. Method for preparing antihypertensive agent
CA2411261A1 (en) * 2000-06-01 2001-12-06 Robert C. Kevorkian Use of ace inhibitors for treatment of patients suffering from behavioral disorders
ATE328596T1 (de) 2001-03-16 2006-06-15 Suntory Ltd Autonomsystem kontrollagentien und gesundheitsgetränke und -nahrungsmittel
EP1879465A1 (en) * 2005-02-09 2008-01-23 Unilever N.V. Composition comprising peptide
RU2005128993A (ru) 2005-09-08 2007-03-20 Общество С Ограниченной Ответственностью Исследовательский Центр "Комкон" (Ru) Средство для коррекции стресс-индуцируемых нейромедиаторных, нейроэндокринных и метаболических нарушений, а также способ профилактики и лечения сопутствующих им паталогических состояний

Also Published As

Publication number Publication date
TW201039839A (en) 2010-11-16
US20120015882A1 (en) 2012-01-19
CN102448480A (zh) 2012-05-09
EP2412379A1 (en) 2012-02-01
CA2756107A1 (en) 2010-09-30
WO2010110439A1 (ja) 2010-09-30
KR20110136879A (ko) 2011-12-21
SG174456A1 (en) 2011-10-28
JP5677937B2 (ja) 2015-02-25
JPWO2010110439A1 (ja) 2012-10-04
MX2011010077A (es) 2011-10-11
EP2412379A4 (en) 2012-11-21

Similar Documents

Publication Publication Date Title
EP2918222A4 (en) LIVING, MENTAL AND PERSONAL HEALTH INFORMATION PLATFORM
GB2536582B (en) Diesel oxidation catalyst with NOx adsorber activity
BR112015006996A2 (pt) método para reduzir a quantidade de enxofre em uma composição que compreende enxofre, e, composição.
LTPA2017007I1 (lt) Terapiniai agentai, skirti prieskydinės liaukos hormono lygio sumažinimui
GB2475740B (en) Catalysts for treating transient NOx emissions
DK3382016T3 (da) Polypeptider med xylanaseaktivitet og polynukleotider, der koder for dem
LT2847304T (lt) Inžinerijos būdu sukurtų kuro žaliavų su sumažintu chloro kiekiu gamybos būdas
BR112013017851A2 (pt) método para reduzir níveis de colágeno de c-telopeptídeo do tipo ii
BRPI1007561A2 (pt) método para revitalizar uma composição contendo betume, e, composição
GB201411274D0 (en) Improvements in and relating to neurostimulating devices for treating pain, improving function and other nervous system related conditions.
SG11201502713QA (en) Compositions, structures and methods for neural regeneration
ZA201104464B (en) Coal rope distributor with replaceable wear components
FI20125294L (fi) Menetelmä pyrolyysiöljyn jalostamiseksi, käsitelty pyrolyysiöljy ja sen käyttö
EP2971259A4 (en) SYNERGISTIC ADDITIVES FOR ELECTROCHEMICAL CELLS HAVING GALVANICALLY FELT FUEL
BRPI0913362A2 (pt) método para produzir carvão pulverizado.
DK2756078T3 (da) Sammensætninger, der omfatter enzymer med endo-1, 4-beta- xylanaseaktivitet og enzymer med endo-1,3(4)-betaglucanaseaktivitet
BR112015002739A2 (pt) métodos para intensificar, melhorar ou sustentar saúde e/ou função cognitiva em mamíferos, e para tratar ou prevenir um declínio em saúde e/ou função cognitiva em mamíferos
DK2751354T3 (da) Ovenlysvindue med forbedret anslagslistekapsel
EP2770449A4 (en) MULTI-TYPE DESIGN DEVICE, MULTIKART DESIGN PROCESS, PROGRAM AND COMPUTER READABLE RECORDING MEDIUM
BR112012006437A2 (pt) composições e métodos para tratamento do diabetes e outros distúrbios
EP2768931A4 (en) PROCESS FOR REDUCING THE DEVELOPMENT OF HYDROGEN SULFIDE FROM ASPHALT AND SULFIDE DEVELOPMENT OF HEAVY FUEL OILS FROM ASPHALT AND HEAVY FUEL OILS
EP2844486A4 (en) ARRANGEMENT AND METHOD FOR SERVICING AN INKJET PRINTER
BR112014028635A2 (pt) projétil e cartucho isentos de chumbo , e , método para reduzir o desgaste entre um projétil e uma arma
BR112012021236A2 (pt) método para produzir composição de isocianato modificada por uretonimina, e, composição de isocianato modificada por uretonimina
EP2619722A4 (en) CONTROLLING THE EXPANSION OF A WEBSITE BEHAVIOR

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2383 DE 06-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.